Henry P. Foote1, Huali Wu2, Stephen J. Balevic1,2, Elizabeth J. Thompson1,2, Kevin D. Hill1,2, Eric M. Graham3, Christoph P. Hornik1,2, Karan R. Kumar1,2,*
Congenital Heart Disease, Vol.18, No.3, pp. 295-313, 2023, DOI:10.32604/chd.2023.026262
Abstract Background: Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) frequently receive intra-operative methylprednisolone (MP) to suppress CPB-related inflammation; however, the optimal dosing strategy and efficacy of MP remain unclear. Methods: We retrospectively analyzed all infants under 90 days-old who received intra-operative MP for cardiac surgery with CPB from 2014–2017 at our institution. We combined real-world dosing data from the electronic health record (EHR) and two previously developed population pharmacokinetic/pharmacodynamic models to simulate peak concentration (Cmax) and area under the concentration-time curve for 24 h (AUC24) for MP and the inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10). We evaluated the relationships… More >
Graphic Abstract
Login
Register
